At this time, we can only study the effects of immunotherapies in skin cancer patients who have a kidney transplant, if they are willing to accept the potential risk of transplant rejection and subsequent initiation of dialysis.
After 16 weeks of treatment, investigators found that tacrolimus and prednisone were not enough to prevent organ loss in kidney transplant recipients with skin cancer.
[
add
]
[
|
|
...
]